Pascal and Francis Bibliographic Databases

Help

Export

Selection :

Permanent link
http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28599981

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

Author
SAUSVILLE, Edward1 ; LORUSSO, Patricia2 ; ZABLUDOFF, Sonya4 ; AGBO, Felix4 ; OAKES, Patricia4 ; SENDEROWICZ, Adrian4 ; CARDUCCI, Michael3 ; CARTER, Judith1 ; QUINN, Mary F1 ; MALBURG, Lisa2 ; AZAD, Nilofer3 ; COSGROVE, David3 ; KNIGHT, Richard4 ; BARKER, Peter4
[1] Marlene and Stewart Greenebaum Cancer Center, University of Maryland, 22 S. Greene Street, Baltimore, MD 21201, United States
[2] Karmanos Cancer Center, Wayne State University School of Medicine, Detroit, MI, United States
[3] Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, United States
[4] AstraZeneca, Wilmington, DE, United States
Source

Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 3, pp 539-549, 11 p ; ref : 28 ref

CODEN
CCPHDZ
ISSN
0344-5704
Scientific domain
Medical oncology; Pharmacology drugs
Publisher
Springer, Heidelberg
Publication country
Germany
Document type
Article
Language
English
Author keyword
AZD7762 Chk1 Pharmacokinetics Phase I Safety Solid tumors
Keyword (fr)
Anticancéreux Association médicamenteuse Essai clinique phase I Gemcitabine Homme Inhibiteur de la tyrosine kinase Pharmacocinétique Stade avancé Toxicité Traitement Tumeur solide Voie intraveineuse Escalade de dose Serine/threonine-protein kinase Chk1 Antimétabolite Cancer Dérivé de la pyrimidine Fluor Composé organique Pyrimidine nucléoside Tumeur maligne
Keyword (en)
Antineoplastic agent Drug combination Phase I trial Gemcitabine Human Tyrosine kinase inhibitor Pharmacokinetics Advanced stage Toxicity Treatment Solid tumor Intravenous administration Dose escalation Antimetabolic Cancer Pyrimidine derivatives Fluorine Organic compounds Pyrimidine nucleoside Malignant tumor
Keyword (es)
Anticanceroso Asociación medicamentosa Ensayo clínico fase I Gemcitabina Hombre Inhibidor tyrosine kinase Farmacocinética Estadio avanzado Toxicidad Tratamiento Tumor sólido Vía intravenosa Antimetabólito Cáncer Pirimidina derivado Fluor Compuesto orgánico Pirimidina nucleósido Tumor maligno
Classification
Pascal
002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R01 General aspects

Discipline
Pharmacological treatments
Origin
Inist-CNRS
Database
PASCAL
INIST identifier
28599981

Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS

Access to the document

Searching the Web